12 terminated. 12 Phase 2, 2 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 12 | Terminated 12 |
| Phase 1 | 2 | Terminated 2 |
| Phase 3 | 1 | Terminated 1 |
Follow PET scan: new trials by email Literature Review of PET scan trials Research Report on PET scan
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing a New Combination of Anti-cancer Drugs in Patients Newly Diagnosed With Ewing Sarcoma Who Have Cancer That Has Spread to Other Parts of the Body Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration - CIC-Rearranged Sarcoma, Metastatic Ewing Sarcoma | Phase 2 / Phase 3 | Terminated | Children's Oncology Group | 2 | 2025-11-10 | 2026-10-05 |
| Immunotherapy With or Without Radiation Therapy for Metastatic Urothelial Cancer Biospecimen Collection, Bone Scan, Computed Tomography - Metastatic Urothelial Carcinoma, Platinum-Resistant Urothelial Carcinoma | Phase 2 | Terminated | National Cancer Institute (NCI) | 1 | 2022-11-22 | 2025-08-17 |
| 68Ga-PSMA-11 PET for the Diagnosis of Metastatic Castration Resistant Prostate Cancer 68Ga-PSMA-11, Positron Emission Tomography (PET) - Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma | Phase 2 | Terminated | Thomas Hope | 15 | 2021-09-28 | 2026-05-15 |
| 68Ga-PSMA-11 PET/CT for the Diagnosis of Bone Metastases in Patients With Prostate Cancer and Biochemical Progression During Androgen Deprivation Therapy Computed Tomography, Gallium Ga 68 Gozetotide, Positron Emission Tomography - Biochemically Recurrent Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone | Phase 2 | Terminated | Jonsson Comprehensive Cancer Center | 22 | 2021-06-16 | 2022-10-21 |
| Testing the Addition of an Anti-cancer Drug, Hu5F9-G4 (Magrolimab), to the Usual Chemotherapy Treatment (Mogamulizumab) in T-Cell (a Type of Immune Cell) Lymphoma That Has Returned After Treatment or Does Not Respond to Treatment Biospecimen Collection, Computed Tomography, Magrolimab - Mycosis Fungoides, Recurrent Mycosis Fungoides | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 8 | 2021-04-06 | 2025-10-16 |
| Gallium-68 Prostate Specific Membrane Antigen PET in Diagnosing Patients With Thyroid Cancer Gallium Ga 68-labeled PSMA-11, Magnetic Resonance Imaging, Positron Emission Tomography (PET) - Thyroid Gland Carcinoma | Phase 2 | Terminated | University of California, San Francisco | 12 | 2018-03-19 | 2021-06-29 |
| Functional Imaging of T-Cell Activation With [18F]F-AraG in Urothelial Carcinoma Patients Receiving Neoadjuvant Therapy or Patients With Cancer Receiving Standard of Care Anti-PD-1/L1 Fluorine F 18 Ara-G, Positron Emission Tomography, Magnetic Resonance Imaging - Bladder Cancer | Phase 2 | Terminated | Lawrence Fong | 4 | 2017-03-07 | 2020-01-21 |
| GA-68 DOTA-TOC of Somatostatin Positive Malignancies Computed Tomography (CT), Gallium Ga 68-Edotreotide, Magnetic Resonance Imaging (MRI) - Neuroendocrine Tumor, Paraganglioma | Phase 1 / Phase 2 | Terminated | University of California, San Francisco | 300 | 2014-06-23 | 2019-11-12 |
| R-ICE and High-Dose Cyclophosphamide With PET/CT for Diffuse Large B-Cell Non-Hodgkin's Lymphoma Rituximab, Cyclophosphamide, Doxorubicin - Non-Hodgkin's Lymphoma | Phase 2 | Terminated | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 27 | 2009-01-01 | 2018-09-25 |
| Phase II of Naltrexone in Hormone-Refractory Metastatic Breast Cancer naltrexone, PET scan - Breast Cancer | Phase 2 | Terminated | Masonic Cancer Center, University of Minnesota | 13 | 2006-07-01 | 2017-12-28 |
| Rituximab, Combination Chemotherapy, and 90-Yttrium Ibritumomab Tiuxetan for Patients With Stage I or II Non-Hodgkin's Lymphoma rituximab, prednisone, cyclophosphamide - Contiguous Stage II Adult Diffuse Large Cell Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Phase 2 | Terminated | National Cancer Institute (NCI) | 62 | 2004-12-01 | 2017-05-25 |
| Sorafenib Tosylate in Treating Patients With Locally Advanced, Metastatic, or Locally Recurrent Thyroid Cancer sorafenib tosylate, laboratory biomarker analysis, pharmacological study - Anaplastic Thyroid Cancer, Insular Thyroid Cancer | Phase 2 | Terminated | National Cancer Institute (NCI) | 25 | 2004-10-01 | 2014-01-16 |
Prostatic Neoplasms (2) · Thyroid Neoplasms (2) · Urinary Bladder Neoplasms (2) · Adenocarcinoma, Follicular (1) · Breast Neoplasms (1) · Carcinoid Tumor (1) · Carcinoma, Transitional Cell (1) · Lymphoma (1) · Lymphoma, B-Cell, Marginal Zone (1) · Lymphoma, Large B-Cell, Diffuse (1) · Lymphoma, Non-Hodgkin (1) · Mycosis Fungoides (1) · Neuroblastoma (1) · Neuroendocrine Tumors (1) · Paraganglioma (1)
National Cancer Institute (NCI) (4) · University of California, San Francisco (2) · Children's Oncology Group (1) · Jonsson Comprehensive Cancer Center (1) · Lawrence Fong (1) · Masonic Cancer Center, University of Minnesota (1) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1) · Thomas Hope (1)
United States (12)
Bhuvana A Setty (1) · Douglas Yee, MD (1) · Himanshu Nagar (1) · Ivan A de Kouchovsky, MD (1) · Jeremie Calais, MD (1) · Lawrence Fong, MD (1) · Lode Swinnen, MD (1) · Manisha Shah (1) · Michael S Khodadoust (1) · Robert Flavell, MD, PhD (1) · Thomas A Hope, MD (1) · Thomas Witzig (1)
N01CM62206 (1), N01CM62207 (1), P30CA016058 (1), U01CA076576 (1), U10CA021115 (1), U10CA180821 (1), U10CA180886 (1), UM1CA186717 (1)